<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297867</url>
  </required_header>
  <id_info>
    <org_study_id>28113265</org_study_id>
    <nct_id>NCT02297867</nct_id>
  </id_info>
  <brief_title>Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis</brief_title>
  <official_title>Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gwo Xi Stem Cell Applied Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gwo Xi Stem Cell Applied Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators study was to investigate the safety and efficacy of autologous
      ADSCs for the clinical treatment of liver cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One milliliter of cell suspension will be injected intrahepatically under sonographic
      guidance using a gauge-18 needle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2015</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MELD</measure>
    <time_frame>1-6 month</time_frame>
    <description>MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula:MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>ADSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADSCs</intervention_name>
    <description>autologous ADSCs</description>
    <arm_group_label>ADSCs</arm_group_label>
    <other_name>hADSCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver cirrhosis investigators with age 20 to 80 years (both inclusive).

          2. Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis)

          3. Investigators without rare disorder

          4. Coagulation normalities

          5. Investigators without autoimmune disorder

          6. Investigators without Acquired Immune Deficiency Syndrome

          7. Investigators without cancer

          8. Investigators BMI ＞ 15

        Exclusion Criteria:

          1. Pregnant women

          2. Investigators with acute stroke in one month and unconsciousness

          3. Investigators with acute myocardial infarction or acute heart failure

          4. Investigators with serious liver dysfunction and coagulation dysfunction and ascites
             mild higher

          5. Investigators with acute respiratory failure or pneumonia

          6. Kidney Failure: BUN ＞ 50

          7. Anemia: Hematocrit ＜ 25

          8. Investigators diagnosed with liver cancer or liver metastatic carcinoma

          9. Investigators with liver abscess

         10. Investigators with acute Hepatitis

         11. Investigators with acute infective

         12. Liver cirrhosis patients with HBV or HCV

         13. Investigators diagnosed with carcinoma and receiving treatment

         14. Investigators with Schizophrenia or melancholia

         15. Investigators received serious surgical operations in 3 months

         16. Investigators unable to control hypertension (SBP ＞ 180 mmHg, DBP ＞ 110 mmHg) or
             diabetes (AC sugar ＞ 200 mg/dl)

         17. Others can't fit into the trial evaluate by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CMU B Hospital</last_name>
    <role>Study Director</role>
    <affiliation>China Medical University Beigang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Beigang Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Beigang</state>
        <zip>65152</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwo Xi Stem Cell Applied Technology Co., Ltd.</name>
      <address>
        <city>Hsinchu</city>
        <zip>30261</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Harn HJ, Lin SZ, Hung SH, Subeq YM, Li YS, Syu WS, Ding DC, Lee RP, Hsieh DK, Lin PC, Chiou TW. Adipose-derived stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function. Cell Transplant. 2012;21(12):2753-64. doi: 10.3727/096368912X652959. Epub 2012 Jul 5.</citation>
    <PMID>22776464</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gwo Xi Stem Cell Applied Technology Co., Ltd.</investigator_affiliation>
    <investigator_full_name>Sabrina Huang</investigator_full_name>
    <investigator_title>China Medical University Beigang Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CRO</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

